Phase II study of second-line gemcitabine in sensitive or refractory small cell lung cancer.
about
Cancer stem cells in small cell lung cancerGemcitabine-(5'-phosphoramidate)-[anti-IGF-1R]: molecular design, synthetic organic chemistry reactions, and antineoplastic cytotoxic potency in populations of pulmonary adenocarcinoma (A549)Treatment options for small cell lung cancer - do we have more choice?A systematic analysis of efficacy of second-line chemotherapy in sensitive and refractory small-cell lung cancerReview of the management of relapsed small-cell lung cancer with amrubicin hydrochloride.Simultaneous Dual Selective Targeted Delivery of Two Covalent Gemcitabine Immunochemotherapeutics and Complementary Anti-Neoplastic Potency of [Se]-MethylselenocysteineAnti-Neoplastic Cytotoxicity of Gemcitabine-(C4-amide)-[anti-EGFR] in Dual-combination with Epirubicin-(C3-amide)-[anti-HER2/neu] against Chemotherapeutic-Resistant Mammary Adenocarcinoma (SKBr-3) and the Complementary Effect of Mebendazole.Chemotherapy for small cell lung cancer: a comprehensive reviewSynthesis of Gemcitabine-(C4-amide)-[anti-HER2/neu] Utilizing a UV-Photoactivated Gemcitabine Intermediate: Cytotoxic Anti-Neoplastic Activity against Chemotherapeutic-Resistant Mammary Adenocarcinoma SKBr-3.Relapsed small cell lung cancer: treatment options and latest developments.Optimal drugs for second-line treatment of patients with small-cell lung cancer.Gemcitabine-(C4-amide)-[anti-HER2/neu] Anti-Neoplastic Cytotoxicity in Dual Combination with Mebendazole against Chemotherapeutic-Resistant Mammary Adenocarcinoma.Anti-Neoplastic Cytotoxicity of Gemcitabine-(C4-amide)-[anti-HER2/neu] in Combination with Griseofulvin against Chemotherapeutic-Resistant Mammary Adenocarcinoma (SKBr-3).Second-line treatments of small-cell lung cancers.Preclinical Evaluation of the Short-Term Toxicity of 4-(N)-Docosahexaenoyl 2´, 2´- Difluorodeoxycytidine (DHA-dFdC).
P2860
Q26767026-9AD86927-28CD-4E1D-9450-030ADBA6DBC8Q33578254-9C641C8B-F530-4A15-9148-8AE502BB374BQ33723735-2D0A0F70-F668-4A26-80DD-F7109B93DA51Q34313435-6B1DC1C3-EEFF-437D-98C6-EC0F5F03E9A6Q34789076-ED55F367-239C-4481-A474-FA03E47BF86EQ35222776-3AE9C71A-90ED-4460-A1C2-CFC05A81D5A4Q35237773-6C5799C2-BA77-4350-8E6B-06A26F13E509Q35569379-3C185A5A-A35B-42AB-A48A-00173CD4BB36Q35892041-BC6DF833-1B3A-4361-B982-CFB617138C04Q37598178-2513A560-CEC0-4E38-A6A4-19D39F9ECFF1Q38734204-52470A59-F171-45A3-838B-61B238A74529Q40649082-E741D276-C344-4099-8AEA-07BD56EC600FQ40678981-FE20BC80-0B06-454E-AC12-3CF427964D78Q47789861-C3AAA70D-167F-45C2-879C-71D0C272DB8EQ52779258-7C9C4433-55D3-47DC-8FA0-0FA5A5D7B981
P2860
Phase II study of second-line gemcitabine in sensitive or refractory small cell lung cancer.
description
2003 nî lūn-bûn
@nan
2003 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Phase II study of second-line ...... actory small cell lung cancer.
@ast
Phase II study of second-line ...... actory small cell lung cancer.
@en
type
label
Phase II study of second-line ...... actory small cell lung cancer.
@ast
Phase II study of second-line ...... actory small cell lung cancer.
@en
prefLabel
Phase II study of second-line ...... actory small cell lung cancer.
@ast
Phase II study of second-line ...... actory small cell lung cancer.
@en
P2093
P1433
P1476
Phase II study of second-line ...... actory small cell lung cancer.
@en
P2093
Anthony Jaslowski
Gary Shapiro
James McGovern
Joan H Schiller
KyungMann Kim
Maria Quisumbing
Peter Beatty
Robert Witte
Tien Hoang
P304
P356
10.1016/S0169-5002(03)00273-3
P577
2003-10-01T00:00:00Z